Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Colorectal Neoplasms 19Colonic Neoplasms 9Pancreatic Neoplasms 8Esophageal Neoplasms 7Stomach Neoplasms 6Rectal Neoplasms 5Adenocarcinoma Of Esophagus 5Ovarian Neoplasms 4Neoplasm Metastasis 4Lymphoma, Large B-Cell, Diffuse 4Cholangiocarcinoma 4Carcinoma, Non-Small-Cell Lung 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Neoplasms 3Endometrial Neoplasms 3Adenocarcinoma 3Recurrence 2Lymphoma, Follicular 2Lung Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Hepatocellular 2Biliary Tract Neoplasms 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Small Bowel Adenocarcinoma 1Prostatic Neoplasms 1

Interventions

sugemalimab 1pegaspargase 1fludarabine phosphate 1Whole-Body Irradiation 1Tacrolimus 1Sirolimus 1Peripheral Blood Stem Cell Transplantation 1Oxaliplatin 1Mycophenolic Acid 1Methotrexate 1Melphalan 1Gemcitabine 1Etoposide 1Cyclosporine 1Cyclophosphamide 1Busulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Extranodal NK-T-Cell × Oxaliplatin × 30 days × Clear all
NCT05700448 2026-05-27

Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma

CStone Pharmaceuticals

Phase 3 Not yet recruiting
150 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡